Watertown, Mass., September 1, 2026 – Remix Therapeutics (Remix), Inc., a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced that management will participate in the following upcoming investor conferences:

• Peter Smith, Ph.D., Co-Founder and Chief Executive Officer of Remix, will present a corporate overview at the 21st Annual Wells Fargo Healthcare Conference on Tuesday, September 8, 2026, at 10:15 a.m. ET in Boston.
• Remix management will participate in 1x1 meetings at the Cantor Global Healthcare Conference 2026 on Wednesday, September 9, 2026, in New York City.

About Remix Therapeutics
Remix Therapeutics is a clinical-stage biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and address disease drivers at their origin. Remix's REMaster™ technology platform leverages cutting-edge data science, biomolecular sciences and chemistry approaches to identify orally administered compounds that modulate gene expression. Remix's innovative therapeutic approach led to the discovery of REM-422, an RNA processing modulator in oncology, now being evaluated in a Phase 1/2 clinical study to treat acute myeloid leukemia (AML), and a Phase 1 clinical study in high-risk myelodysplastic syndrome (HR-MDS) and adenoid cystic carcinoma (ACC).